Real-World Healthcare Resource Utilization Patterns Among Patients With Non-Small Cell Lung Cancer Treated With Amivantamab Monotherapy
Author(s)
David M. Waterhouse, MD, MPH1, Iris Lin, PhD2, Laura Morrison, MPH3, Bruno Emond, MSc3, Marie-Hélène Lafeuille, MA3, Yuxi Wang, MSc3, Lilian Diaz, MScPH3, Patrick Lefebvre, BA, MA3, Dexter D Waters, MSPH2.
1Oncology Hematology Care, Cincinnati, OH, USA, 2Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA, 3Analysis Group, Inc., Montreal, QC, Canada.
1Oncology Hematology Care, Cincinnati, OH, USA, 2Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA, 3Analysis Group, Inc., Montreal, QC, Canada.
Presentation Documents
OBJECTIVES: Among patients with non-small cell lung cancer (NSCLC), ~19-24% have epidermal growth factor receptor (EGFR) mutations. Amivantamab received United States Food and Drug Administration (FDA) approvals in advanced NSCLC on 05/21/2021 for patients with EGFR exon 20 insertions (Exon20Ins) who progressed after platinum-based chemotherapy (PBC), on 03/01/2024 for first-line (1L) EGFR Exon20Ins, and for 1L (08/20/2024) and second-line (2L) (09/19/2024) EGFR exon 19 deletion and L858R. This study describes real-world healthcare resource utilization (HRU) among patients with advanced NSCLC receiving amivantamab monotherapy.
METHODS: Komodo Research Data closed claims (01/01/2016-10/31/2023) were used to analyze adult patients with lung cancer (ICD-10-CM code: C34) who initiated amivantamab monotherapy on or after 05/21/2021 in second-or-later line (2L+) following PBC (with/without immunotherapy) for advanced NSCLC. Data availability aligned with amivantamab’s FDA approval for EGFR Exon20Ins after progression on PBC. All-cause HRU per-patient-per-month (PPPM) was assessed during the amivantamab line of therapy (LOT) and all LOTs preceding amivantamab.
RESULTS: Among 97 patients initiating amivantamab monotherapy in 2L+ (mean age: 59.2 years; 61.9% female), median duration of each LOT preceding amivantamab was 7.1 months; over a median follow-up of 6.5 months post-amivantamab initiation, median LOT duration for 2L+ amivantamab was 5.3 months. The proportion of patients initiating amivantamab in 2L was 52.6% (N=51), 3L was 30.9% (N=30) and 4L+ was 16.5% (N=16). Mean outpatient service use was 6.09 days PPPM before amivantamab initiation and 6.60 during amivantamab treatment. Mean inpatient admissions PPPM were 0.05 prior to amivantamab and 0.08 during amivantamab treatment. Mean emergency room visits were 0.19 days PPPM before amivantamab and 0.21 during amivantamab treatment.
CONCLUSIONS: Among real-world patients with advanced NSCLC receiving amivantamab monotherapy following PBC, HRU was similar before and during treatment with amivantamab, suggesting that amivantamab does not contribute to an increase in medical services compared to treatment regimens used in earlier LOTs.
METHODS: Komodo Research Data closed claims (01/01/2016-10/31/2023) were used to analyze adult patients with lung cancer (ICD-10-CM code: C34) who initiated amivantamab monotherapy on or after 05/21/2021 in second-or-later line (2L+) following PBC (with/without immunotherapy) for advanced NSCLC. Data availability aligned with amivantamab’s FDA approval for EGFR Exon20Ins after progression on PBC. All-cause HRU per-patient-per-month (PPPM) was assessed during the amivantamab line of therapy (LOT) and all LOTs preceding amivantamab.
RESULTS: Among 97 patients initiating amivantamab monotherapy in 2L+ (mean age: 59.2 years; 61.9% female), median duration of each LOT preceding amivantamab was 7.1 months; over a median follow-up of 6.5 months post-amivantamab initiation, median LOT duration for 2L+ amivantamab was 5.3 months. The proportion of patients initiating amivantamab in 2L was 52.6% (N=51), 3L was 30.9% (N=30) and 4L+ was 16.5% (N=16). Mean outpatient service use was 6.09 days PPPM before amivantamab initiation and 6.60 during amivantamab treatment. Mean inpatient admissions PPPM were 0.05 prior to amivantamab and 0.08 during amivantamab treatment. Mean emergency room visits were 0.19 days PPPM before amivantamab and 0.21 during amivantamab treatment.
CONCLUSIONS: Among real-world patients with advanced NSCLC receiving amivantamab monotherapy following PBC, HRU was similar before and during treatment with amivantamab, suggesting that amivantamab does not contribute to an increase in medical services compared to treatment regimens used in earlier LOTs.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE130
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology